Kiora Pharmaceuticals Inc (KPHMW) — 8-K Filings

8-K Filings (14)

• Kiora Pharmaceuticals Files 8-K for Regulation FD Disclosure — Aug 13, 2025 Risk: low
  Kiora Pharmaceuticals, Inc. filed an 8-K on August 13, 2025, reporting a Regulation FD Disclosure. The filing details events that occurred on August 12, 2025. K
• Kiora Pharmaceuticals Files 8-K — Jun 4, 2025 Risk: low
  Kiora Pharmaceuticals, Inc. filed an 8-K on June 4, 2025, reporting on the submission of matters to a vote of security holders and financial statements. The com
• Kiora Pharmaceuticals Files 8-K for Material Agreement — Jun 3, 2025 Risk: medium
  Kiora Pharmaceuticals, Inc. filed an 8-K on June 3, 2025, reporting a material definitive agreement entered into on May 30, 2025. The filing also includes Regul
• Kiora Pharmaceuticals Announces Board and Executive Changes — Jan 15, 2025 Risk: medium
  Kiora Pharmaceuticals, Inc. announced on January 10, 2025, a change in its board of directors and executive compensation arrangements. The filing details the de
• Kiora Pharmaceuticals Files 8-K — Oct 29, 2024 Risk: low
  Kiora Pharmaceuticals, Inc. filed an 8-K on October 29, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The co
• Kiora Pharmaceuticals Files 8-K — Jul 30, 2024 Risk: low
  Kiora Pharmaceuticals, Inc. filed an 8-K on July 30, 2024, reporting other events and financial statements. The company, formerly known as Eyegate Pharmaceutica
• Kiora Pharmaceuticals Appoints New CMO, Elects Director — Jul 1, 2024 Risk: medium
  Kiora Pharmaceuticals, Inc. announced on June 28, 2024, the appointment of Dr. Michael L. Weiser as Chief Medical Officer and the election of Ms. Jennifer L. Si
• Kiora Pharmaceuticals Files 8-K on Security Holder Rights — Jun 7, 2024 Risk: medium
  Kiora Pharmaceuticals, Inc. filed an 8-K on June 7, 2024, reporting material modifications to security holder rights and other events. The company, formerly kno
• Kiora Pharmaceuticals Files 8-K with Corporate Updates — May 3, 2024 Risk: low
  Kiora Pharmaceuticals, Inc. filed an 8-K on May 3, 2024, reporting events as of May 1, 2024. The filing indicates changes to the company's articles of incorpora
• Kiora Pharmaceuticals Files 8-K on Financials — Mar 25, 2024 Risk: low
  Kiora Pharmaceuticals, Inc. filed an 8-K on March 25, 2024, reporting on its financial condition and results of operations. The filing also includes financial s
• KIORA PHARMACEUTICALS Files 8-K for Reg FD, Financials — Feb 12, 2024 Risk: low
  KIORA PHARMACEUTICALS, INC. filed an 8-K on February 12, 2024, primarily to disclose information under Regulation FD and to file financial statements and exhibi
• KIORA PHARMACEUTICALS Enters Material Agreement, Sells Unregistered Equity — Feb 1, 2024
  KIORA PHARMACEUTICALS INC filed an 8-K on February 1, 2024, reporting an "Entry into a Material Definitive Agreement" and "Unregistered Sales of Equity Securiti
• KIORA PHARMACEUTICALS Enters Material Definitive Agreement — Jan 31, 2024
  KIORA PHARMACEUTICALS INC (KPRX) entered into a material definitive agreement on January 25, 2024, which is a significant event for the company. This filing ind
• Kiora Pharma (KPRX) Receives Nasdaq Delisting Notice for Bid Price Rule — Jan 16, 2024
  KIORA PHARMACEUTICALS INC (KPRX) announced on January 16, 2024, that it received a delisting notice from Nasdaq because its common stock failed to maintain a mi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX